Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 11/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PLD2 | O14939 | 1/20 | 0.38 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223397 | 0.85 | NPY5R (0.50) | SCDNPY5RAVPR1A | |
| SCHEMBL3229428 | 0.83 | SCD (0.47) | DGAT1SCDTP53CYP3A4MAPT | |
| SCHEMBL3220824 | 0.82 | SCD (0.45) | SCD | |
| SCHEMBL3220004 | 0.80 | NPY5R (0.46) | SCDNPY5RAVPR1A | |
| SCHEMBL3224120 | 0.78 | SCD (0.45) | SCD | |
| SCHEMBL3229221 | 0.77 | SCD (0.45) | SCD | |
| SCHEMBL3223079 | 0.76 | SCD (0.48) | SCD | |
| SCHEMBL3232971 | 0.76 | SCD (0.46) | SCD | |
| SCHEMBL3221535 | 0.75 | SCD (0.66) | SCD | |
| SCHEMBL3219618 | 0.75 | SCD (0.47) | SCDAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | DGAT1 2579/4885SCD 1/4885TP53 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.